Payment overview · 2025
General Payments
$283.60
7 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Robinson, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROANOKE, AL · NPI 1194748731
Verified facts
What the public records show
CMS Open Payments records show Michael Robinson, DO received $283.60 in general payments during 2025 across 7 reported records.
Innovation Technologies Inc accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $153.55 | 54.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.89 | 15.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.85 | 13.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.04 | 8.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.27 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $283.60 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $153.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.89 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 391 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 123 |
| Lisinopril | Lisinopril | 307 | 95 |
| Omeprazole | Omeprazole | 277 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 76 |
| Pioglitazone Hcl | Pioglitazone Hcl | 222 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 64 |
| Gabapentin | Gabapentin | 214 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 59 |
| Prednisone | Prednisone | 202 | 147 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 57 |
| Meloxicam | Meloxicam | 180 | 50 |
| Carvedilol | Carvedilol | 177 | 42 |
| Azithromycin | Azithromycin | 170 | 132 |
| Metformin Hcl | Metformin Hcl | 160 | 47 |
| Losartan Potassium | Losartan Potassium | 154 | 48 |
| Potassium Chloride | Potassium Chloride | 145 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 30 |
| Furosemide | Furosemide | 136 | 47 |
| Mounjaro | Tirzepatide | 135 | 24 |
| Montelukast Sodium | Montelukast Sodium | 134 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 48 |
| Terazosin Hcl | Terazosin Hcl | 124 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 123 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 31 |
| Sertraline Hcl | Sertraline Hcl | 103 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 37 |
| Simvastatin | Simvastatin | 88 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 87 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 28 |
| Temazepam | Temazepam | 80 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 22 |
| Famotidine | Famotidine | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 26 |
| Atenolol | Atenolol | 73 | 21 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 21 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 19 |
| Allopurinol | Allopurinol | 61 | 20 |
| Eliquis | Apixaban | 61 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Levofloxacin | Levofloxacin | 49 | 38 |
| Diazepam | Diazepam | 48 | 18 |
| Enalapril Maleate | Enalapril Maleate | 48 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 39 |
| Fluconazole | Fluconazole | 44 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 13 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 11 |
| Mupirocin | Mupirocin | 32 | 27 |
| Baclofen | Baclofen | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 15 |
| Estradiol | Estradiol | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 24 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Tramadol Hcl | Tramadol Hcl | 25 | 16 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 16 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $283.60 · 7 records | Innovation Technologies Inc | Dexcom G6 Transmitter, IRRISEPT, OTEZLA, Ozempic, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error